QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)

Oppenheimer Equities Analysts Lift Earnings Estimates for Gamida Cell Ltd. (NASDAQ:GMDA)

Saturday, May 14, 2022 | MarketBeat

Gamida Cell Ltd. (NASDAQ:GMDA - Get Rating) - Analysts at Oppenheimer lifted their FY2025 EPS estimates for Gamida Cell in a note issued to investors on Tuesday, May 10th. Oppenheimer analyst M. Breidenbach now anticipates that the company will earn $0.32 per share for the year, up from their prior estimate of $0.31.

GMDA has been the subject of a number of other research reports. JMP Securities reiterated a "buy" rating and issued a $17.00 price target on shares of Gamida Cell in a research note on Tuesday, February 1st. Piper Sandler reduced their price target on shares of Gamida Cell from $13.00 to $6.00 in a research report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Gamida Cell in a research note on Wednesday, March 16th. Finally, Zacks Investment Research cut shares of Gamida Cell from a "buy" rating to a "hold" rating in a research note on Monday, April 4th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $12.39.

Shares of GMDA stock traded up $0.16 during trading on Friday, reaching $2.36. The company's stock had a trading volume of 5,601 shares, compared to its average volume of 1,609,648. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 1.63. The stock's 50-day moving average price is $3.46 and its 200 day moving average price is $3.20. Gamida Cell has a 1-year low of $2.10 and a 1-year high of $6.94. Gamida Cell (NASDAQ:GMDA - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34). During the same quarter last year, the firm earned ($0.34) EPS.


Institutional investors and hedge funds have recently made changes to their positions in the stock. Morgan Stanley increased its holdings in shares of Gamida Cell by 152.1% during the second quarter. Morgan Stanley now owns 72,586 shares of the company's stock valued at $465,000 after purchasing an additional 43,794 shares during the period. BlackRock Inc. boosted its position in Gamida Cell by 4.6% during the 3rd quarter. BlackRock Inc. now owns 361,759 shares of the company's stock worth $1,418,000 after acquiring an additional 15,761 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Gamida Cell by 226.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 79,025 shares of the company's stock valued at $310,000 after buying an additional 54,820 shares during the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of Gamida Cell by 288.8% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,724,201 shares of the company's stock valued at $6,759,000 after buying an additional 1,280,694 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Gamida Cell by 153.3% in the 3rd quarter. Renaissance Technologies LLC now owns 531,184 shares of the company's stock worth $2,082,000 after purchasing an additional 321,484 shares during the last quarter. Hedge funds and other institutional investors own 47.12% of the company's stock.

About Gamida Cell (Get Rating)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Further Reading

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Gamida Cell right now?

Before you consider Gamida Cell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gamida Cell wasn't on the list.

While Gamida Cell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.